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Background. Previous research on the combined association of 25-hydroxyvitamin D [25(OH)D] and exocrine pancreas insuf-
ﬁciency may have been limited by restricted age variability and a lack of representation of both body weight and body mass index.
TherearestilltoofewconclusivereportsaboutconspicuousvitaminDmetabolismaccordingtopancreaticfecalelastase1(FE1)in
obese patients. Methods. Between May 2004 and July 2008, we investigated in 125 female patients with obesity syndrome at an
average age of approximately 52.9 years as well as in age-matched 80 healthy female controls the prevalence of pancreas insuf-
ﬁciency.SerumlevelsofPTH,totalcalcium,andD3 vitaminscalcitriolandcalcifediol,aswellastheconcentrationoffecalelastase1
(FE1) were determined in patients and controls. Results. In 75 female nondiabetic patients with obesity syndrome (BMI 35 ≤
40kg/m2), calcifediol was markedly decreased (25.0 ± 4.9ng/mL) compared to controls (50.2 ± 14.7nmol/L; P<0.01). FE1 level
was signiﬁcantly decreased in obese subjects compared to controls (P<0.01). Calcifediol was signiﬁcantly lower in patients with
morbid obesity (for calcifediol, P<0.05). Conclusion. In obese females, pancreatic FE1 in feces conﬁrms the extent of vitamin D
supply,andthusshowsavitaminD3 deﬁciency,dependingonthelossofstoolcontent.Thereseemstobeaconnectionbetweenthe
loss of exocrine function and the increasing body mass index. Pancreas insuﬃciency, as detected by low FE1 concentrations, is fre-
quent in obese patients. However, the BMI is an additional factor for lowered fecal excretion of FE1.
In honour of the 90th birthday of Professor Dr.med.Dr. h.c. Konrad Seige, Martin-Luther-University Halle, Saale,
Germany
1.Introduction
Vitamin D deﬁciency, as reﬂected by circulating 25-hydrox-
yvitamin D (25[OH]D) levels less than 20ng/mL, is preva-
lent in as many as one-half of middle-aged to elderly adults
in developed countries [1]. Additionally, vitamin D status is
strongly associated with variation in subcutaneous and espe-
cially visceral adiposity [2]. Female patients without any his-
tory of diabetes or pancreatitis but with deﬁciency of fecal
elastase 1 show alterations of the vitamin D metabolism.
Theseresultedfromtheimpaired exocrine pancreasfunction
as compared to indirect test method: estimation of fecal
elastase [3].
Deﬁciencyofelastase1infeces(FE1)haspreviouslybeen
regarded to be revealed sensitivities of 14%, 87%, and 95%
for the Cambridge grades I, II, and III, and correlated sig-
niﬁcantly with this classiﬁcation of severity of chronic pan-
creatitis [4]. FE1 is, compared to the “gold standard,” the
secretin caerulein test, a highly sensitive and speciﬁc tubeless
pancreatic function test [5]. In the diagnosis of chronic pan-
creatitis there is a parallelism between exocrine function and
ERCP results [6], even using FE1 for description of pancrea-
ticinsuﬃciency[7,8].Oneﬁeldwhichhasuntilnowreceived
little attention is the changes of vitamin D3 serum levels sub-
jected to the diﬀerent severity grades of pancreatic exocrine
insuﬃciency. The consequences of exocrine insuﬃciency2 ISRN Gastroenterology
mightberelevantforserumlevelsoflipidsolublevitaminD3.
However, conspicuous vitamin D deﬁciency in patients with
chronic pancreatitis has only been described by very few au-
thorsuntilnow[9–13].Accordingly,oneofthemostobvious
causes of elevated PTH serum levels, impaired and lowered
vitamin D3, exocrine insuﬃciency with consecutive malassi-
milation and resulting insuﬃcient vitamin D-supply should
be further investigated.
Exocrine insuﬃciency of pancreas is frequent in both
type 1 and type 2 diabetes mellitus [14]. The connection bet-
ween obesity syndrome and the manifestation of diabetes
mellitus is well accepted. Overweight or obese subjects with-
out metabolic syndrome were at increased risk for diabetes
[15].
Although the lowered FE1 has been investigated in sub-
jects with both diabetes mellitus and hypovitaminosis D,
fecal pancreas elastase 1 in subjects with obesity syndrome
and vitamin D deﬁciency has not been demonstrated. Thus
theaimofthepresentstudywasundertakentodeterminethe
impact of body weight and nutritional status on FE1 and
25-hydroxyvitamin D (25[OH]D) serum levels.
2.MaterialandMethods
2.1. Patients. Between May 2004 and July 2008, 125 female
outpatients (aged from 52.9 ± 10.51 years) with obesity syn-
drome were included in our studies. They were admitted to
hospital for work-up extreme weight gain, abnormalities of
body composition, obesity, or infertility syndrome. Exclu-
sion criteria were male sex, age under 35 or over 65 years,
steatorrhea, pancreatic-biliary obstructions, actual and rel-
evant alcohol consumption, medication with inﬂuence on
osteological and/or endocrine parameters (heparin, ketoco-
nazol, glucocorticoids, thiacide-diuretics, psychopharmaco-
logical agents, and carbamazepin), altered kidney function,
pregnancy, and chronic or severe concomitant diseases.
Based on the assumption of an interaction between exocrine
andendocrine pancreatic functionwe excluded patients with
a diabetes mellitus [15]. The selected patients were studied
in detail with history and physical examination, including
detailed neurological examination. Body mass index (BMI)
was calculated from the height and weight measurements of
the patients. To examine adiposity and body size separately,
we repeated multivariable analyses of adiposity measures
within subgroups deﬁned by BMI category (<25, 30 to <35,
35 to <40, and ≥40kg/m2).
Data regarding total vitamin D intake from supplements
anddietwereobtainedusingadetailedfood-frequencyques-
tionnaire.80healthyfemalesubjectsbetween39and60years
of age with a BMI ≤ 25kg/m2 served as controls [3].
2.2. Biochemical Measurements. Blood samples were taken
from all participants every morning at the same ﬁxed time.
We did not consider the speciﬁc circannual periodic of the
vitamin D metabolism. The speciﬁc serum parameters of
this study were PTH (“intact PTH 1–84 IRMA Kit” from
Nichols Institute Diagnostics, San Juan Capistrano, Califor-
nia, USA), calcitriol (“1,25 (OH)2 Vitamin D”-kit from
Immun Diagnostik, Bensheim, Germany; competitive radio
receptor assay), and calcifediol (“25 (OH)2 Vitamin D” kit
from Immun Diagnostik, Bensheim, Germany; competitive
protein binding assay). Pancreatic elastase 1 (“Pankreatic
Elastase 1”-kit from ScheBo Biotech, Giessen, Germany;
double-sided enzyme immuno-assay) was determined in the
feces of all participants.
2.3. Statistical Analysis. Results are presented by mean values
and standard deviation. The following methods were applied
for statistical analysis: a single factor variance analysis, the
Scheﬀ´ e-Test, the nonparametric Kurskal-Wallis-Test with
subsequent Dunn-Test, as well as the t-test for independent
random samples with and without the Welche’s correction.
Pearson’s correlation coeﬃcient and also the non-parametric
Spearman correlation coeﬃcient were applied for investigat-
ing any connections [16, 17].
3. Results
3.1. Prevalence of Vitamin D Deﬁciency. A total of 125 obese
female patients and 80 controls were included in the study.
The 25 (OH)2 vitamin D deﬁciency (<20ng/mL) was more
frequent among individuals with high BMI (30 to <35, 35
to <40 and ≥40kg/m2) compared with those with low BMI;
(<25 57.7% versus 9.7%, P<0.01).
Furthermore, the vitamin D metabolism did not dif-
fer signiﬁcantly within the various subgroups: BMI 30 <
35kg/m2 (N = 25); 35 < 40kg/m2 (N = 75) > 40kg/m2
(N = 25) as well as extremely decreased compared to the
controls (P<0.01; Tables 1 and 3): calcitriol in patients with
obesity was slightly decreased, but did not diﬀer signiﬁcantly
within the various BMI groups (P>0.05). Calcifediol was
not signiﬁcantly diﬀerent within the various BMI groups
(P = 0.07). Nevertheless, both D3-vitamins were lower in
female obese patients.
3.2. Prevalence of Fecal Pancreas Elastase 1 Deﬁciency. The
majority of women with obesity syndrome presented a
lowered fecal excretion of pancreatic elastase 1. These
observations were aggravated by an elevated BMI of the
subjects (Table 1, P<0.01, Table 2). Additionally, FE1 in
obese patients correlated signiﬁcantly with both D3-vitamins
(P<0.01; Table 3).
Concerning estimation of PTH levels in serum, there was
no correlation both between the fecal elastase 1 and the
D3-vitamins calcitriol and calcifediol. In 125 female obese
patients only three patients (48, 51, 53 years) showed milder
cases of newly diagnosed primary hyperparathyroidism. At
diagnosis of primary hyperparathyroidism events involving
gastric disorders, for example, gastric ulcers, were prevalent
inhistoryofbothpatients.However,therewasnoevidenceof
anacutepancreatitisincasehistoryorabdominalultrasound
examination.
4. Discussion
We found an increased prevalence of lowered fecal excretion
of pancreatic elastase 1 (FE1) in female obese patients. This
alteration of the fecal excretion of FE1 is independent onISRN Gastroenterology 3
Table 1:Age,faecalelastase1,calcitriol,andcalcifediol(means ±standarddeviation)infemalepatientswithobesitysyndromeandcontrols.
P<0.05 indicates a signiﬁcant diﬀerence between the patient-collectives allotted by the body mass index (BMI).
Parameters Controls (N = 80) BMI[kg/m2] P
I3 0≤ 35 (N = 25) II 35 ≤ 40 (N = 75) III ≥40 (N = 25)
Age (years) 54.8 ±12,1 51.6 ±9,3 53.5 ±7.05 2 .4 ±8.6n . s .
Faecal elastase 1 (µg/g) 665.9 ±117.4 414.7 ±71.9 299.6 ±44.8 224.1 ±69.5 P<0.01
Calcitriol (pg/mL) 41.0 ±8.34 1 .7 ±8.23 4 .4 ±5.13 0 .5 ±6.1n . s .
Calcifediol (ngl/mL) 50.2 ±14.73 4 .1 ±12.52 5 .0 ±4.91 8 .8 ±7.3 P<0.01
PTH (pg/mL) 41.3 ±10.24 4 .8 ±21.35 1 .4 ±15.75 4 .1 ±20.9n . s .
Table 2: Comparison of serum PTH, calcitriol and calcifediol, and
fecalelastase1content,betweendiﬀerentpatient-collectivesallotted
by the body mass index (BMI) and controls. P<0.05 indicates a
signiﬁcant diﬀerence between patients with BMI and controls.
Parameters
Comparison of error probabilities of
variation between patients and
controls (N = 80) concerning BMI
(kg/m2)
Controls
(N = 80)
30 ≤ 35
(N = 25)
>35
(N = 100)
Faecal elastase 1 (µg/g) P<0.01 P<0.01 P<0.01
Calcitriol P<0.01 n.s. P<0.01
Calcifediol P<0.01 P = 0.05 P<0.01
PTH n.s. n.s. n.s.
Table 3: Correlation between vitamin D3 and elastase 1 in feces in
obese female patients. P<0.05 indicates a signiﬁcant correlation.
N = 125 Vitamin D3
Parameter Calcitriol Calcifediol
Elastase 1 in feces
Correlation Pearson 0.721 0.658
PP < 0.05 P<0.01
disturbancesofglucosemetabolism,disordersofpancreas,or
gall bladder.
Data about exocrine insuﬃciency of pancreas in obesity
syndrome are rare. Concerning the body mass index, Hahn
et al. [18] demonstrated the loss of an inﬂuence on exocrine
pancreas function by using a secretion caerulein test in di-
abetic subjects with diﬀerent BMI. Using the FE1 for estima-
tion of exocrine pancreas function, diabetic individuals with
excess weight (BMI > 25) may be at increased risk for under-
lying exocrine pancreatic insuﬃciency. In diabetes mel-
litus (n = 42), 11 patients with excess weight presented a
FE1 < 200microg/g, whereas four patients with a BMI < 25
presented this result (P<0.05) [19]. On the other hand, the
excess weight does not seem to aﬀect the pancreas exocrine
functionwhenitisnotassociatedwithdiabetesmellitus[19].
To our knowledge, this is the ﬁrst study dealing with the
link between FE1 and the respective serum levels of vitamin
D3 in obese subjects. Assuming that FE1 in feces is the repre-
sentative marker for an exocrine insuﬃciency during a chro-
nic pancreatitis, Dutta et al. [9] already described a frequent
lossoflipidsolublevitamins,evenvitaminD,inpatientswith
chronic pancreatitis and exocrine insuﬃciency. Accordingly,
the present study showed a highly signiﬁcant correlation bet-
ween FE1 and vitamin D3, which was more pronounced for
calcifediol than calcitriol. Under the aspect of an exocrine
pancreas insuﬃciency with resulting malabsorption for vit-
amin D in patients with chronic pancreatitis, FE1 gains sig-
niﬁcance hereby as a pancreas function test. Therefore, vita-
min D3 deﬁciency would be very dependent upon the sever-
ity grade of exocrine insuﬃciency, represented here by the
FE1 in obese patients. Assuming that steatorrhea is the ob-
vious symptom of exocrine insuﬃciency in patients with
chronic pancreatitis, as reported by Twersky and Bank [20],
that its existence as well as occurrence is dependent upon
the severity of exocrine dysfunction and fat supply in food,
the results from Dutta et al. [9], Dibble et al. [10], and also
Nakamura et al. [11] contradict the above-mentioned state-
ment. Dutta et al. [9] could not ﬁnd any connection between
measured lipid soluble vitamins (including calcifediol) and
severity of steatorrhea in patients with chronic pancreatitis.
Likewise, Dibble et al. [10] obtained the same results by ap-
plying calcifediol only, and Nakamura et al. [11] by applying
all lipid soluble vitamins (including calcitriol and calcife-
diol), except vitamin E, in all patients. Also, Haaber et al.
[13] described the lack of diﬀerence for calcitriol and calci-
fediol depending on the exocrine insuﬃciency as well as on
the duration of the disease in patients with chronic pancre-
atitis. Nevertheless, all these observations are not suitable to
invalidate the link of elastase 1 values in feces, severity of
disease, and vitamin D deﬁciency in patients with exocrine
insuﬃciency. According to Twersky and Bank [20]a n d
DiMagno et al. [21], the parameter of steatorrhea is too vari-
able for a precise description of exocrine function of the
pancreas,andtherefore,statementsbyDuttaetal.[9],Dibble
et al. [10], and Nakamura et al. [11] are in this sense less
representative. The results from Haaber et al. [13]a l s ol o s e
their signiﬁcance, because enzymes were substituted in pa-
tients with exocrine pancreatic insuﬃciency. On the basis
that under normal circumstances 80–90% of experimentally
applied, radioactively labelled vitamin D3 is absorbed by the
intestines, although only 40% in patients with pancreatic
insuﬃciency [22], exocrine pancreatic function gains sig-
niﬁcance and supports our own results with corresponding
evaluation of FE1. Furthermore, it is conceivable that FE1
plays an independent role with regard to vitamin D3 supply
in the organism. Since by passing the intestines, FE1 changes
to a complete protein sterol complexity by loading neutral4 ISRN Gastroenterology
steroids [23], and since vitamin D3 is also a sterol molecule,
there is a hypothetical cross-link here. Therefore, there are
still queries regarding the importance of sterol linking in
elastase 1 in interaction with its excretion status for vitamin
D3 supply.
As vitamin D deﬁciency and hyperparathyroidism are re-
latively common, a coexistence of these conditions must be
considered. Vitamin D deﬁciency may increase the severity
of primary hyperparathyroidism (presence of larger adeno-
mas, higher PTH levels, and greater bone turnover). Never-
theless, some of the biochemical features of primary hyper-
parathyroidism can be masked by the coexisting vitamin D
deﬁciency leading to an inappropriate therapeutic manage-
ment of these patients [24]. Although several lines of evi-
denceindicatethatserumPTHmaybeassociatedwithmeta-
bolic disturbances, to our knowledge, only few studies have
addressed the combined eﬀect of serum PTH and vitamin
D on metabolic syndrome and visceral adiposities. These re-
ports, however, diverge in their conclusions. The ﬁnding of
a close relationship between metabolic syndrome and PTH
level is in contrast with the negative results of a previous
study of severely obese subjects [25, 26], but extend the re-
sults from a study of older mainly nonobese men to be
valid in adult Caucasian treatment seeking morbidly obese
women and men. Further, although Hjelmesæth et al. found
a signiﬁcant inverse correlation between 25(OH)D and
PTH, the group could not conﬁrm any association between
25(OH)D and metabolic syndrome as shown by others [25,
27].
Our study also had limitations. First, the cross-sectional
design makes it diﬃcult to establish a cause-eﬀect relation-
ship. Second, our results may not be valid in diagnosing dia-
betes mellitus by using an oral glucose tolerance test. The
exclusion criteria of a pancreatitis were performed only by
ultrasound examination. We did use a magnetic resonance
imagingforthedescriptionofthepancreasmorphology.Fin-
ally, we cannot exclude the possibility that referral of patients
to a tertiary care centre might have introduced a selection
bias.
In summary, obese female patients present a lowered ex-
cretion of FE1 and show alterations of the vitamin D meta-
bolism. These resulted from the impaired exocrine pancreas
function as compared to indirect test method: estimation of
FE1. The estimation of FE1 is a well-founded indirect test for
determination of vitamin D supply in obese female subjects
as well.
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